Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis

Qiao,Weiwei; Zhang,Weili; Shao,Shuhong; Gai,Yusheng; Zhang,Mingxiang

doi:10.3892/mmr.2015.3596

Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis

Authors:
- Weiwei Qiao
- Weili Zhang
- Shuhong Shao
- Yusheng Gai
- Mingxiang Zhang
View Affiliations

Affiliations: Department of Diagnostics, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Department of Cardiology, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Department of Medical Psychology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Shandong University, Qilu Hospital, Jinan, Shandong 250012, P.R. China
Published online on: April 7, 2015 https://doi.org/10.3892/mmr.2015.3596
Pages: 1631-1638
Copyright: © Qiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of aldosterone on vascular endothelial cells and the viability of poly (ADP‑ribose) polymerase 1 (PARP1) in cells, and to examine the molecular mechanisms underlying the effects of aldosterone on vascular endothelial cell injury. Cultured endothelial cells were treated either with different concentrations of aldosterone for the same duration or with the same concentrations of aldosterone for different durations, and the levels of apoptosis and activity of PARP1 in the cells were detected, respectively. Aldosterone receptor antagonists or PARP1 inhibitors were added to cells during treatment with aldosterone and the levels of apoptosis and activity of PARP1 were detected. As the concentration of aldosterone increased or the treatment time increased, the number of apoptotic cells and the activity of PARP1 increased. The aldosterone receptor antagonists and PARP1 inhibitors inhibited the increase of apoptosis and PARP1 activity caused by aldosterone treatment. Aldosterone activated the activity of PARP1 via the aldosterone receptor, inhibiting cell proliferation and inducing apoptosis. Treatment with PARP1 may be used as a target for vascular diseases caused by aldosterone at high concentrations.

View Figures

View References

1	Hillaert MA, Lentjes EG, Beygui F, Kemperman H, Asselbergs FW, et al: Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. Am Heart J. 162:585–596. 2011. View Article : Google Scholar : PubMed/NCBI
2	Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO and März W: Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 31:1237–1247. 2010. View Article : Google Scholar : PubMed/NCBI
3	Vantrimpont P, Rouleau JL, Ciampi A, et al: Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J. 19:1552–1563. 1998. View Article : Google Scholar : PubMed/NCBI
4	Sun Y, Zhang J, Lu L, Chen SS, Quinn MT and Weber KT: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 161:1773–1781. 2002. View Article : Google Scholar : PubMed/NCBI
5	Pitt B, Bakris G, Ruilope LM, DiCarlo L and Mukherjee R; EPHESUS Investigators: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 118:1643–1650. 2008. View Article : Google Scholar : PubMed/NCBI
6	Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG and Richards AM: Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 29:2489–2496. 2008. View Article : Google Scholar : PubMed/NCBI
7	Calhoun DA: Aldosterone and cardiovascular disease: smoke and fire. Circulation. 114:2572–2574. 2006. View Article : Google Scholar : PubMed/NCBI
8	Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S and Aviram M: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 109:2213–2220. 2004. View Article : Google Scholar : PubMed/NCBI
9	Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R and Yamamoto H: Vasular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth-muscle cells. J Biol Chem. 269:24316–24320. 1994.PubMed/NCBI
10	Godon C, Cordelières FP, Biard D, Giocanti N, Méqnin-Chanet F, Hall J and Favaudon V: PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 36:4454–4464. 2008. View Article : Google Scholar : PubMed/NCBI
11	Schultz N, Lopez E, Saleh-Gohari N and Helleday T: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31:4959–4964. 2003. View Article : Google Scholar : PubMed/NCBI
12	Claybon A, Karia B, Bruce C and Bishop AJ: PARP1 suppresses homologous recombination events in mice in vivo. Nucleic Acids Res. 38:7538–7545. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chiarugi A and Moskowitz MA: Cell biology. PARP-1 – a perpetrator of apoptotic cell death? Science. 297:200–201. 2002. View Article : Google Scholar : PubMed/NCBI
14	Rho YH, Chung CP, Oeser A, et al: Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 61:1580–1585. 2009. View Article : Google Scholar : PubMed/NCBI
15	Pacher P and Szabó C: Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 25:235–260. 2007. View Article : Google Scholar : PubMed/NCBI
16	Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J and Horiuchi M: Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 26:917–921. 2006. View Article : Google Scholar : PubMed/NCBI
17	Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H and Miyazaki M: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 46:1135–1139. 2005. View Article : Google Scholar : PubMed/NCBI
18	Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348:1309–1321. 2003. View Article : Google Scholar : PubMed/NCBI
19	Diefenbach J and Bürkle A: Introduction to poly(ADP-ribose) metabolism. Cell Mol Life Sci. 62:721–730. 2005. View Article : Google Scholar : PubMed/NCBI
20	Tsifetaki N, Georqiadis AN, Alamanos Y, Fanis S, Arqyropoulou MI and Drosos AA: Subclinical atherosclerosis in scleroderma patients. Scand J Rheumatol. 39:326–329. 2010. View Article : Google Scholar : PubMed/NCBI
21	Jaffe EA, Nachman RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 52:2745–2756. 1973. View Article : Google Scholar : PubMed/NCBI
22	Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, Marto J, Iqlehart DJ and Lazaro JB: Concordant and opposite roles of DNA-PK and the “facilitator of chromatin transcription” (FACT) in DNA repair, apoptosis and necrosis after cisplatin. Mol Cancer. 10:742011. View Article : Google Scholar
23	Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
24	Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J and Yepes M: Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience. 171:1256–1264. 2010. View Article : Google Scholar : PubMed/NCBI